Search
Rofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnRofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. … On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.
Icalcaprant
go.drugbank.com/drugs/DB21651InvestigationalIcalcaprant has a monoisotopic molecular weight of 406.2 Da. … Icalcaprant is under investigation in clinical trial NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Olomorasib
go.drugbank.com/drugs/DB21697InvestigationalOlomorasib has a monoisotopic molecular weight of 528.08 Da. … Olomorasib is under investigation in clinical trial NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalDevelopment was discontinued due to concerns over hepatotoxicity observed in animal studies. … Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.
Pamufetinib
go.drugbank.com/drugs/DB20752InvestigationalPamufetinib has a monoisotopic molecular weight of 518.14 Da. … The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study).
RAV12
go.drugbank.com/drugs/DB05140InvestigationalRAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. … RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid.
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation.
Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideOfirnoflast
go.drugbank.com/drugs/DB21679InvestigationalOfirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da. … The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor.
Dimethyl sulfone
go.drugbank.com/drugs/DB14090InvestigationalMixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula PowderProducts: Nn Bio-MSM 750